Chronic fatigue syndrome: Lactic acid bacteria may be of therapeutic value

Medical Hypotheses

Volumn 60, Issue 6, 2003, Pages 915-923

  Logan, Alan C ^a   Rao, A Venket ^b   Irani, Dinaz ^c  

^a CFS FM Integrative Care Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL FATTY ACID; TRACE ELEMENT;

ABSORPTION; ALLERGY; ANTIOXIDANT ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; BIFIDOBACTERIUM; CELL ACTIVATION; CHRONIC FATIGUE SYNDROME; COLONY FORMING UNIT; CYTOKINE PRODUCTION; DIET THERAPY; DRUG MECHANISM; HELICOBACTER PYLORI; HELPER CELL; HUMAN; INTESTINE EPITHELIUM; INTESTINE FLORA; LACTIC ACID BACTERIUM; LACTOBACILLUS; MALABSORPTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; STRESS;

BACTERIA (MICROORGANISMS);

EID: 0037410286     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00096-3     Document Type: Review

References (138)

1. Komaroff A. L., Buchwald D. Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis 1991; 13(suppl. 1): S8-11.
2. Komaroff A. L., Fagioli L. R., Geiger A. M. et al. An examination of the working case definition of chronic fatigue syndrome. Am J Med 1996; 100: 56-64.
3. Aaron L. A., Burke M. M., Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia and temporomandibular disorder. Arch Int Med 2000; 160: 221-227.
4. Gomborone J. E., Gorard D. A., Dewsnap P. A. et al. Prevalence of irritable bowel syndrome in chronic fatigue. J R Coll Physicians Lond 1996; 30: 512-513.
5. Pataraca-Montero R., Antoni M., Fletcher M. A., Kumas N. G. Cytokine and other immunologic markers in chronic fatigue syndrome and their relation to neuropsychological factors. Appl Neuropsychol 2001; 8: 51-64.
6. Butt H. L., Dunstan R. H., McGregor N. R., Roberts T. K., Harrison T. L., Granger J. R. Faecal microbial growth inhibition m chronic fatigue/pain patients. Proceedings of the AHMF International Clinical and Scientific Conference; 1998 Feb 12-14; Sydney, Australia.
7. Butt H. L., Dunstan R. H., McGregor N. R., Roberts T. K. Bacterial colonosis in patients with persistent fatigue. Proceedings of the AHMF International Clinical and Scientific Conference; 2001 Dec 1-2; Sydney, Australia.
8. Holzapfel W. H., Haberer P., Snel J., Schillinger U. Huis In't Veld JHJ. Overview of gut flora and probiotics. Int J Food Microbiol 1998; 41: 85-101.
9. Evaldson G., Heimdahl A., Kager L., Nord C. E. The normal human microflora. Scand J Infect Dis 1982; 35(suppl): 9-15.
10. Orrhage K., Nord C. E. Bifidobacteria and lactobacilli in human health. Drugs Exptl Clin Res 2000; 26: 95-111.
11. Mitsuoka T. Recent trends in research on intestinal flora. Bifidobacteria Microflora 1982; 1: 3-24.
12. Kopp-Hoolihan L. Prophylactic and therapeutic uses of probiotics: A review. J Am Diet Assoc 2001; 101: 229-238.
13. Modler H. W., McKellar R. C., Yaguchi M. Bifidobacteria and bifidogenic factors. Can Inst Food Sci Technol J 1990; 23: 29-41.
14. Kaizu H., Sasaki M., Nakajima H., Suzuki Y. Effect of antioxidative lactic acid bacteria on rats fed a diet deficient in vitamin E. J Dairy Sci 1993; 76: 2493-2499.
15. Lin M. Y., Yen C. L. Inhibition of lipid peroxidation by lactobacillus acidophilus and bifidobacterium longum. J Agric Food Chem 1999; 47: 3661-3664.
16. Lin M. Y., Yen C. L. Antioxidant ability of lactic acid bacteria. J Agric Food Chem 1999; 47: 1460-1466.
17. Lin M. Y., Chang F. J. Antioxidative effect of intestinal bacteria bifidobacterium longum ATCC 15708 and lactobacillus acidophilus ATCC 4356. Dig Dis Sci 2000; 45: 1617-1622.
18. Abbas A. K., Murphy K. M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
19. Cross M. L., Stevenson L. M., Gill H. S. Anti-allergy properties of fermented foods: An important immunoregulatory mechanism of lactic acid bacteria? Int Immunopharm 2001; 1: 891-901.
20. Cross M. L., Gill H. S. Can immunoregulatory lactic acid bacteria be used as dietary supplements to limit allergies? Int Arch Allergy Immunol 2001; 125: 112-119.
21. Bjorksten B., Naaber P., Sepp E., Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999; 29: 342-346.
22. Gill H. S., Rutherfurd K. J., Cross M. L., Gopal P. K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic bifidobacterium lactis HN019. Am J Clin Nutr 2001; 74: 833-839.
23. Gill H. S., Rutherfurd K. J., Cross M. L. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: An investigation of age-related immunological changes. J Clin Immunol 2001; 21: 264-271.
24. Ohashi T., Minamishima Y., Yokokura T., Mutai M. Induction of resistance in mice against cytomegalovirus by cellular components of Lactobacillus casei. Biotherapy 1989; 1: 89-95.
25. Aattouri N., Bouras M., Tome D., Marcos A., Lemonnier D. Oral ingestion of lactic-acid bacteria by rats increases lymphocyte proliferation and interferon gamma production. Br J Nutr 2002; 87: 367-373.
26. Kato I., Tanaka K., Yokokura T. Lactic acid bacterium potently induces the production of interleukin-12 and interferon gamma by mouse splenocytes. Int J Immunopharmacol 1999; 21: 121-131.
27. Matsuzaki T., Yamazaki R., Hashimoto S., Yokokura T. The effect of oral feeding of Lactobacillus casei strain Shirota on immunoglobulin E production in mice. J Dairy Sci 1998; 81: 48-53.
28. Maassen C. B. M., van Holton-Neelan C., Balk F., Heijne den Bak-Glashouwer M. et al. Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine 2000; 18: 2613-2623.
29. Hessle C., Hanson L. A., Wolo A. E. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin Exp Immunol 1999; 116: 276-282.
30. Murosaki S., Yamamoto Y., Ho K., Inokuchi T. et al. Heat-killed Lactobacillus plantarum L-137 suppresses naturally fed antigen-specific IgE production by stimulation of IL-12 production in mice. J Allergy Clin Immunol 1998; 102: 57-64.
31. Miettinen M., Matikainen S., Vuopio-Varkila J., Pirhonen J. et al. Lactobacilli and streptococci induce interleukin-12(IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Infect Immun 1998; 66: 6058-6062.
32. Shida K., Takahashi R., Iwadate E., Takamizawa K. et al. Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and immunoglobulin GI responses and systemic anaphylaxis in a food allergy model. Clin Exp Allergy 2002; 32: 563-570.
33. Sutas Y., Hurme M., Isolauri E. Down-regulation of anti-CD3 antibody-induced IL-4 production by bovine caseins hydrolysed with Lactobacillus GG-derived enzymes. Scand J Immunol 1996; 43: 687-689.
34. Shida K., Makino K., Morishita A., Takamizawa K. et al. Lactobacillus casei inhibits antigen-induced IgE secretion through regulation of cytokine production in splenocyte cultures. Int Arch Allergy ImmunoI 1998; 115: 278-287.
35. Kankaanpaa P. E., Yang B., Kallio H. P., Isolauri E., Salminen S. J. Influence of probiotic supplemented infant formula on composition of plasma lipids in atopic infants. J Nutr Biochem 2002; 13: 364-369.
36. Black P. N., Sharpe S. Dietary fat and asthma: Is there a connection? Eur Respir J 1997; 10: 6-12.
37. Kankaanpaa P., Sutas Y., Salminen S., Lichtenstein A., Isolauri E. Dietary fatty acids and allergy. Ann Med 1999; 31: 282-287.
38. Sukhov S. V., Kalamkarova L. I., Ilchenko L. A., Zhangabylov A. K. Microfloral changes in the small and large intestines of chronic enteritis patients on diet therapy including sour milk products. Vopr Pitan 1986; 4: 14-17.
39. Kirjavainen P. V., Arvola T., Salminen S. J., Isolauri E. Abberant composition of gut microbiota of allergic infants: A target of bifidobacterial therapy at weaning? Gut 2002; 51: 51-55.
40. Balish E., Warner T. Enterococcus faecalis induces inflammatory bowel disease in IL-10 knockout mice. Am J Pathol 2002; 160: 2253-2257.
41. Balsari A., Ceccarelli A., Dubini F., Pese E., Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 185-194.
42. Bayliss C. E., Bradley H. K., Alun Jones V., Hunter J. O. Some aspects of colonic microbial activity in irritable bowel syndrome assocated with food intolerance. Ann Ist Super Sanita 1986; 22: 959-964.
43. Bradley H. K., Wyatt G. M., Bayliss C. E., Hunter J. O. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 1987; 23: 29-32.
44. Wyatt G. M., Bayliss C. E., Lakey A. F., Bradley H. K., Hunter J. O., Alun Jones V. The faecal flora of two patients with food-related irritable bowel syndrome during challenge with symptom-provoking foods. J Med Microbiol 1988; 26: 295-299.
45. Logan A. C., Wong C. Chronic fatigue syndrome: Oxidative stress and dietary modifications. Altern Med Rev 2001; 6: 450-459.
46. Logan A. C. Dietary modifications and fibromyalgia. Complementary Health Pract Rev, 2003 October, in press.
47. Nord C. E., Heimdahl A., Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis 1986; 49(suppl): 64-72.
48. Mangin I., Bourget N., Bouhnik Y., Bisetti N., Simonet J., Decaris B. Identification of Bifidobacterium strains by rRNA gene restriction patterns. Appl Environ Microbiol 1994; 60: 1451-1458.
49. Maxwell P. R., Rink E., Kumar D., Mendall M. A. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002; 97: 104-108.
50. Mendall M. A., Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastronenterol Hepatol 1998; 10: 59-62.
51. Edlund C., Nord C. E. Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections. J Antimicrob Chemother 2000;(suppl. A): 41-48.
52. Orrhage K., Sjostedt S., Nord C. E. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoximine proxetil. J Antimicrob Chemother 2000; 46: 603-611.
53. Pimentel M., Hallegua D., Chow E. J., Wallace D., Bonorris G., Lin H. C. Eradication of small intestinal bacterial overgrowth decreases symptoms in chronic fatigue syndrome: A double blind, randomized study. Gastroenterology 2000; 118: A414.
54. Pimentel M., Chow E. J., Hallegua D., Wallace D., Lin H. C. Small intestinal bacterial overgrowth: A possible association with fibromyalgia. J Musculoskeletal Pain 2001; 9: 107-113.
55. Pimentel M., Chow E. J., Lin H. C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-3506.
56. Sinaii N., Cleary S. D., Ballweg M. L., Nieman L. K., Stratton P. Autoimmune and related diseases among women with endometriosis: A survey analysis. Fertil Steril 2002; 77(suppl. 1): S7-8.
57. Bailey M. T., Coe C. L. Endometriosis is associated with an altered profile of intestinal microflora in female rhesus monkeys. Hum Reprod 2002; 17: 1704-1708.
58. Mathias J. R., Franklin R., Quast D. C., Fraga N. et al. Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: New insights. Fertil Steril 1998; 70: 81-88.
59. Borish L., Schmaling K., DiClementi J. D., Streib J., Negri J., Jones J. F. Chronic fatigue syndrome: Identification of distinct subgroups on the basis of allergy and psychologic variables. J Allergy Clin Immunol 1998; 102: 222-230.
60. Waylonis G. W., Heck W. Fibromyalgia syndrome: New associations. Am J Phys Med Rehabil 1992; 71: 343-348.
61. Locke G. R., Zinsmeister A. R., Talley N. J., Fett S. L., Melton L. J. Risk facytors for irritable bowel syndrome: Role of analgesics and food sensitivities. Am J Gastroenterol 2000; 95: 157-165.
62. Toskes P. P. Bacterial overgrowth of the gastrointestinal tract. Adv Int Med 1993; 38: 387-407.
63. Bouhnik Y., Alain S., Attar A., Flourie B. et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J GastroenteroI 1999; 94: 1327-1331.
64. Holt P. R. Diarrhea and malabsorption in the elderly. Gastroenterol Clin North Am 1990; 19: 345-359.
65. Donaldson R. M. Role of enteric microorganisms in malabsorption. Fed Proc 1967; 26: 1426-1431.
66. King C. E., Toskes P. R. Small intestinal bacterial overgrowth. Gastroenterology 1979; 76: 1035-1055.
67. Tabaqchali S. The pathophysiological role of small intestinal bacterial flora. Scand J Gastroenterol 1970; 5: 139-163.
68. Grant J. E., Veldee M. S., Buchwald D. Analysis of dietary intake and selected nutrient concentrations in patients with chronic fatigue syndrome. J Am Diet Assoc 1996; 96: 383-386.
69. Heap L. C., Peters T. J., Wessely S. Vitamin B status in patients with chronic fatigue syndrome. J R Soc Med 1999; 92: 183-185.
70. Werbach M. R. Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev 2000; 5: 93-108.
71. Moore W. E. C., Cato E. P., Holdeman L. V. Some current concepts in intestinal bacteriology. Am J Clin Nutr 1978; 31: S33-42.
72. Holdeman L. V., Good I. J., Moore W. E. C. Human faecal flora: A variation in bacterial composition within individuals and a possible effect of emotional stress. Appl Environ Microbiol 1976; 31: 359-375.
73. Lizko N. N., Silou V. M., Syrych G. D. Events in the development of dysbacteriosis of the intestines in man under extreme conditions. Nahrung 1984; 28: 599-605.
74. Lizko N. N. Stress and intestinal microflora. Nahrung 1987; 31: 443-447.
75. Goncharova G. I., Lizko N. N., Liawnaia A. M., Shilou V. M., Spitsa T. I. Bifidobacterium flora status of cosmonauts before and after completing space flights. Kosm Biol Aviakosm Med 1981; 15: 14-18.
76. Shilou V. M., Lizko N. N., Borisova O. K., Prokhorov V. Y. Changes in the microflora of man during long-term confinement. Life Sci Space Res 1971; 9: 43-49.
77. Smirnov K. V., Lizko N. N. Problems of space gastroenterology and microenvironment. Nahrung 1987; 31: 563-566.
78. Lizko N. N. Problems of microbial ecology in man space mission. Acta Astronautica 1991; 23: 163-169.
79. Konstantinova I. V., Sonnenfeld G., Lesnyak A. T., Shaffar L. et al. Cellular immunity and lymphokine production during spaceflights. Physiologist 1991; 34(suppl. 1): S52-S56.
80. Lesniak A. T., Pykova M. P., Meshkov D. O., Antropova E. N. et al. Human cellular immunity and space flights. Aviakosm Ekolog Med 1998; 32: 29-35.
81. Berg A., Muller H. M., Rathmann S., Deibert D. The gastrointestinal system - an essential target organ of the athlete's health and physical performance. Exerc ImmunoI Rev 1999; 5: 78-95.
82. Dubos R. J., Schaedler R. W. The effect of diet on the fecal bacterial flora of mice and on their resistance to infection. J Exp Med 1962; 115: 1161-1173.
83. Bailey M. T., Coe C. L. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev Psychobiol 1999; 35: 146-155.
84. Suzuki K., Harasawa R., Yoshitake Y., Mitsuoka T. Effects of crowding and heat stress on intestinal flora, body weight gain, and feed efficiency of growing rats and chicks. Jpn J Vet Sci 1983; 45: 331-338.
85. Schaedler R. W., Dubos R. J. The fecal flora of various strains of mice. Its bearing on their susceptibility to endotoxin. J Exp Med 1962; 115: 1149-1160.
86. Tannock G. W., Savage D. C. Influences of dietary and environmental stress on microbial populations in the gastrointestinal tract. Infect Immun 1974; 9: 591-598.
87. Vikha G. V., Lizko N. N., Korolkov V. I., Rykova M. P. et al. Carbohydrate adaptive substance for prophylaxis of immune disorders and correction of dysbacteriosis. Aviakosm Ekolog Med 1998; 32: 21-25.
88. Timoveyev I., Loseva E., Alekseeva T., Perminova N. Stability to sound stress and changeability in intestinal microflora. Eur Psychiatry 2002; 17(suppl. 1): 200.
89. Cleare A. J., Wessely S. C. Chronic fatigue syndrome: A stress disorder? Br J Hosp Med 1996; 55: 571-574.
90. Chalder T., Power M. T., Wessely S. C. Chronic fatigue in the community: A question of attribution. Psychol Med 1996; 26: 791-800.
91. Friedberg F., Dechene L., McKenzie M. J., Fontanetta R. Symptom patterns in long-duration chronic fatigue syndrome. J Psychosom Res 2000; 48: 59-68.
92. Neerinckx E., Van Houdenhove B., Lysens R., Vertommen HI., Onghena P. Attributions in chronic fatigue syndrome and fibromyalgia syndrome in tertiary care. J Rheumatol 2000; 27: 1051-1055.
93. Clements A., Sharpe M., Simkins S., Borril J., Hawton K. Chronic fatigue syndrome: A qualitative investigation of patients' beliefs about the illness. J Psychosom Res 1997; 42: 615-624.
94. Wessely S., Chalder T., Hirsch S., Pawlikowska T., Wallace P., Wright D. J. M. Postinfectious fatigue: Prospective cohort study in primary care. Lancet 1995; 345: 1333-1338.
95. Theorell T., Blomkvist V., Lindh F., Evengard B. Critical life events, infections, and symptoms during the year preceding chronic fatigue syndrome (CFS): An examination of CFS patients and subjects with a nonspecific life crisis. Psychosom Med 1999; 61: 304-310.
96. Wood G., Bentall R., Goplent M., Edwards R. A comparative psychiatric assessment of patients with chronic fatigue syndrome and muscle disease. Psychol Med 1991; 21: 619-628.
97. Salit I. E. Precipitating factors for the chronic fatigue syndrome. J Psychiatr Res 1997; 31: 59-65.
98. Dobbins J., Natelson B., Btassloff I., Drastal S., Sisto S. Physical, behavioral and psychological risk factors for chronic syndrome: A central role for stress? J Chronic fatigue syndrome 1995; 1: 43-58.
99. Wood G. C., Bentall R. P., Goplert M., Dewey M. El., Edwards R. H. T. The different response of chronic fatigue, neurotic and muscular dystrophy patients to experimental psychological stress. Psychol Med 1994; 24: 357-364.
100. Beh H. C., Connelly N., Charles M. Effect of noise stress on chronic fatigue syndrome patients. J Nerve Ment Dis 1997; 185: 55-58.
101. LaManca J. J., Peckerman A., Sisto S. A., De Luca J., Cook S., Natelson B. H. Cardiovascuar responses of women with chronic fatigue syndrome to stressful cognitive testing before and after strenuous exercise. Psychosom Med 2001; 63: 756-764.
102. Lutgendorf S. K., Antoni M. H., Ironson G. et al. Physical symptoms of chronic fatigue syndrome are exacerbated by the stress of Hurricane Andrew. Psychosom Med 1995; 57: 310-323.
103. Van Houdenhove B., Neerinckx E., Onghena P., Lysens R., Vertommen H. Premorbid 'overactive' lifestyle in chronic fatigue syndrome and fibromyalgia. J Psychosom Res 2001; 51: 571-576.
104. Kavelaars A., Kuis W., Knook L., Sinnema G., Heijnen C. J. Disturbed neuroendocrine-immune interactions in chronic fatigue syndrome. J Clin Endocrinol Metab 2000; 85: 692-696.
105. Paik I., Toh K., Lee C., Kim J., Lee S. Psychological stress may induce increased humoral and decreased cellular immunity. Behav Med 2000; 26: 139-141.
106. Kang D. H., Fox C. Th1 and Th2 cytokine responses to academic stress. Res Nurs Health 2001; 24: 245-257.
107. Marshall G. D., Agarwal S. K., Lloyd C., Cohen L., Henninger E. M., Norris G. J. Cytokine dysregulation associated with exam stress in healthy medical students. Brain Behav Immun 1998; 12: 297-307.
108. Patarca R. Cytokines and chronic fatigue syndrome. Ann NY Acad Sci 2001; 933: 185-200.
109. Rook G. A. W., Zumla A. Gulf War syndrome: Is it due to a systemic shift in cytokine balance towards a Th2 profile? Lancet 1997; 349: 1831-1833.
110. Visser J. T., De Kloet E. R., Nagelkerken L. Altered glucocorticoid regulation of the immune response in chronic fatigue syndrome. Ann NY Acad Sci 2000; 917: 868-975.
111. Visser J., Graffelman W., Blauw B., Haspels I. et al. LPS-induced IL-10 production in whole blood cultures from chronic fatigue syndrome patients is increased but supersensitive to inhibition by dexamethasone. J Neuroimmunol 2001; 119: 343-349.
112. Fulle S., Mecocci P., Fano G., Vecchiel I. et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med 2000; 29: 1252-1259.
113. Manuel Y., Keenoy B., Moorkens G., Vertommen J., Noe M., Neve J., De Leeuw I. Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: Effects of supplementation with magnesium. J Am Coll Nutr 2000; 19: 374-382.
114. Manuel Y., Keenoy B., Moorkens G., Vertommen J., De Leeuw I. Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci 2001; 68: 2037-2049.
115. Richards R. S., Roberts T. K., McGregor N. R., Dunstan R. H., Butt H. L. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Res 2000; 5: 35-41.
116. Ockerman P. Antioxidant treatment of chronic fatigue syndrome. Clin Pract Altern Med 2000; 1: 88-91.
117. Gray J. B., Martinovic A. M. Eicosanoids and essential fatty acid modulation in chronic disease and the chronic fatigue syndrome. Med Hypotheses 1994; 43: 31-42.
118. Horrobin D. F. Post-viral fatigue syndrome, viral infections in atopic eczema, and essential fatty acids. Med Hypotheses 1990; 32: 211-217.
119. Behan P. O., Behan W. M. H., Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand 1990; 82: 209-216.
120. Ozgocmen S., Catal S. A., Ardiocoglu O., Kamanli A. Effect of omega-3 fatty acids in the management of fibromyalgia syndrome. Int J Clin Pharmacol Ther 2000; 38: 362-363.
121. Simenhoff M. L., Dunn S. R., Zollner G. P., Fitzpatrick M. E. D. et al. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-state kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 1996; 22: 92-96.
122. Vanderhoof J. A., Young R. J., Murray N., Kaufman S. S. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998; 27: 155-160.
123. Kanamori Y., Hashizume K., Sugiyama M., Morotomi M., Yuki N. Combination therapy with Bifidobacterium breve, Lactobacillus casei and galactooligosaccharides dramatically improved the intestinal function in a girl with short bowel syndrome. Dig Dis Sci 2001; 46: 2010-2016.
124. Lizko N. N. The dysbacteriosis of extreme states. Antibiot Med Biotekhnol 1987; 32: 184-186.
125. Kafarskaia L. I., Gladko I. A., Efimor B. A., Tarabrina N. P., Skvortsov V. M., Korshunov V. M. The effect of fermented-milk bifidumbacterin on the intestinal microflora of test pilots. Zh Mikrobiol Epidemiol Immunobiol 1992; 4: 12-14.
126. Niedzielin K., Kordecki H., Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299v in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-1147.
127. Brigidi P., Vitali B., Swennen E., Bazzocchi G., Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001; 152: 735-741.
128. Halpern G. M., Prindiville T., Blankenberg M., Hsia T., Gershwin M. E. Treatment of irritable bowel syndrome with lacteol fort: A randomized, double-blind, cross-over trial. Am J Gastroenterol 1996; 91: 1579-1585.
129. Nobaek S., Johansson M. L., Molin G., Ahrne S., Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-1238.
130. Jacobsen C. N., Rosenfeldt Nielsen V., Hayford A. E., Moller P. L. et al. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol 1999; 65: 4949-4956.
131. O'Mahony L., Feeney M., O'Halloran S., Murphy L. et al. Probiotic impact on microbial flora, inflammation and turnout development in IL-10 knockout mice. Aliment Pharmacol Ther 2001; 15: 1219-1225.
132. Doyle K. M., Shaw G. G. The mechanism of the neurotoxic effects of spermidine. Biochem Soc Trans 1994; 22: 386S.
133. Bested A. C., Saunders P. R., Logan A. C. Chronic fatigue syndrome: Neurological findings may be related to blood-brain barrier permeability. Med Hypotheses 2001; 57: 231-237.
134. Lyte M., Varcoe J. J., Bailey M. T. Anxiogenic effect of subclinical bacterial infection in mice in the absence of overt immune activation. Physiol Behav 1998; 65: 63-68.
135. Gasbarrini A., De Luca A., Fiore G., Gambrielli M. et al. Beneficial effects of Helicobacter pylori eradication on migraine. Hepatogastroenterology 1998; 45: 765-770.
136. Gerards C., Leodolter A., Glasbrenner B., Malfertheiner P. H. pylori infection and visceral hypersensitivity in patients with irritable bowel syndrome. Dig Dis 2001; 19: 170-173.
137. Logan A. C. Helicobacter pylori and probiotics. Hosp Physician 2002; 38: 13-14.
138. Mitsuoka T. Intestinal flora and aging. Nutr Rev 1992; 50: 438-446.